KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $562.7 million.

  • Royalty Pharma's Cash from Financing Activities rose 27288.06% to $562.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 39553.19%. This contributed to the annual value of $361.1 million for FY2024, which is 11680.72% up from last year.
  • Royalty Pharma's Cash from Financing Activities amounted to $562.7 million in Q3 2025, which was up 27288.06% from -$507.8 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Cash from Financing Activities peaked at $1.2 billion during Q2 2024, and registered a low of -$1.4 billion during Q3 2023.
  • In the last 5 years, Royalty Pharma's Cash from Financing Activities had a median value of -$228.3 million in 2022 and averaged -$170.2 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 49086.21% in 2023, then soared by 43332.11% in 2024.
  • Over the past 5 years, Royalty Pharma's Cash from Financing Activities (Quarter) stood at -$198.1 million in 2021, then plummeted by 34.07% to -$265.6 million in 2022, then increased by 12.67% to -$231.9 million in 2023, then dropped by 11.24% to -$258.0 million in 2024, then skyrocketed by 318.15% to $562.7 million in 2025.
  • Its last three reported values are $562.7 million in Q3 2025, -$507.8 million for Q2 2025, and -$941.3 million during Q1 2025.